Global Biopharmaceutical CMO Market Projected to Reach USD 76.20 Billion by 2035, Fueled by Rising Biologics Demand and Expanding Outsourcing Strategies – SNS Insider
Capacity Constraints Among Innovator Firms, Accelerating Biologic Pipeline Activity, and Strategic Outsourcing by Pharma Giants Are Propelling Global Biopharmaceutical CMO Market Expansion.
Austin, United States, Feb. 24, 2026 (GLOBE NEWSWIRE) — Biopharmaceutical CMO Market Size & Growth Analysis:
According to SNS Insider, The Biopharmaceutical CMO Market size is estimated at USD 21.16 billion in 2025 and is expected to reach USD 76.20 billion by 2035, growing at a CAGR of 13.67% over 2026-2035. Increased pharmaceutical outsourcing tactics, growing biologic drug development costs, and capacity limitations at pharmaceutical businesses are the main factors propelling the market’s expansion.
Market Size and Forecast:
- Market Size in 2025: USD 21.16 billion
- Market Size by 2035: USD 76.20 billion
- CAGR: 13.67% from 2026 to 2035
- Base Year: 2025
- Forecast Period: 2026–2035
- Historical Data: 2022–2024
Get a Sample Report of Biopharmaceutical CMO Market: https://www.snsinsider.com/sample-request/2938
The U.S. Biopharmaceutical CMO Market is estimated at USD 8.32 billion in 2025 and is expected to reach USD 29.96 billion by 2035, growing at a CAGR of 13.74% over 2026-2035. The U.S. is the largest market for biopharmaceutical contract manufacturing, mostly because to its well-established regulatory framework for biopharmaceutical manufacture, robust contract manufacturing infrastructure, and huge biologics development pipeline.
Rising Biologics Development and Capacity Constraints Propel Market Growth Globally
Growing therapeutic antibody approvals, complicated manufacturing requirements, and pharmaceutical companies limited in-house production capabilities for specialized biologic modalities are the main factors driving the growth of biologics development and capacity constraints, which take center stage as growth drivers for the biopharmaceutical CMO market share. The market’s foundation, the penetration of the contract manufacturing and contract research markets, and the expansion of the market share globally are all being driven by these solutions for outsourced manufacturing and process development.
Major Players Analysis Listed in this Report are
- Lonza Group AG
- Samsung Biologics Co., Ltd.
- Catalent, Inc.
- Boehringer Ingelheim International GmbH
- Thermo Fisher Scientific Inc.
- WuXi Biologics (Cayman) Inc.
- Fujifilm Diosynth Biotechnologies
- AGC Biologics
- Rentschler Biopharma SE
- Recipharm AB
- Abzena plc
- ProBioGen AG
- Binex Co., Ltd.
- Celonic AG
- Cytiva (Danaher Corporation)
- KBI Biopharma, Inc.
- Evonik Industries AG
- Paragon Bioservices, Inc.
- BIOTEC Services International Ltd.
- Wacker Chemie AG
- Batavia Biosciences
- Richter-Helm BioLogics GmbH & Co. KG
- CMC Biologics A/S
- AbbVie Contract Manufacturing
- Emergent BioSolutions Inc.
Biopharmaceutical CMO Market Report Scope
| Report Attributes | Details |
| Market Size in 2025 | US$ 21.16 Billion |
| Market Size by 2035 | US$ 76.20 Billion |
| CAGR | CAGR of 13.67% From 2026 to 2035 |
| Base Year | 2025 |
| Forecast Period | 2026-2035 |
| Historical Data | 2022-2024 |
| Regional Analysis/Coverage | North America (US, Canada), Europe (Germany, UK, France, Italy, Spain, Russia, Poland, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN Countries, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Mexico, Colombia, Rest of Latin America). |
Segmentation Analysis:
By Source
The mammalian segment accounted for the highest revenue share of approximately 67.42% in 2025, owing to superior post-translational modification capabilities. The mammalian segment is anticipated to achieve the highest CAGR of nearly 13.89% during the 2026–2035 period, driven by the continuous advancement in cell line development technologies, and growing therapeutic antibody pipeline.
By Service
By 2025, the contract manufacturing segment contributed the largest revenue share of 63.28% due to extensive capacity requirements for commercial-scale production. The contract research segment is projected to grow at the highest CAGR of about 14.12% between 2026 and 2035 due to the growing need for specialized development services and early-stage product optimization capabilities.
By Product
The biologics segment accounted for the largest share of the biopharmaceutical CMO market with about 58.94%, owing to their dominant position in pharmaceutical pipelines. The segment is also expected to grow at the fastest rate with a CAGR of around 13.92% throughout the forecast period of 2026–2035, as pharmaceutical companies seek comprehensive manufacturing solutions for antibody-drug conjugates.
Need Any Customization Research on Biopharmaceutical CMO Market, Enquire Now: https://www.snsinsider.com/enquiry/2938
Biopharmaceutical CMO Market Segmentation
By Source
- Mammalian
- Non-mammalian
By Service
- Contract Manufacturing
- Process Development
- Contract Research
- Oncology
- Inflammation & Immunology
- Cardiology
- Neuroscience
- Others
By Product
- Biologics
- Monoclonal antibodies (MAbs)
- Recombinant Proteins
- Vaccines
- Antisense, RNAi, & Molecular Therapy
- Others
- Biosimilars
Regional Insights:
With a compound annual growth rate (CAGR) of 15.23%, Asia Pacific is the biopharmaceutical CMO market segment with the fastest rate of growth. This is due to rising awareness of cost-effective manufacturing solutions, government biotechnology development initiatives, and the expansion of pharmaceutical manufacturing capacity in developing countries.
Because of its well-established contract manufacturing infrastructure, robust biologics development pipeline, and growing reliance on outsourcing strategies for specialized production, North America held the largest revenue share of the biopharmaceutical CMO market in 2025, accounting for over 43.67% of the total.
Recent Developments:
- In February 2025, Lonza Group AG (est. 1897) it expanded its mammalian cell culture manufacturing capabilities with next-generation bioreactor systems and AI-driven process optimization, aiming to improve production efficiency and capacity utilization across its global manufacturing network.
- In May 2024, Samsung Biologics Co., Ltd. (est. 2011) launched an enhanced integrated service platform featuring accelerated technology transfer and dedicated production suites across Asian manufacturing facilities, enhancing client flexibility, production timelines, and biosimilar development capabilities.
Exclusive Sections of the Report (The USPs):
- MANUFACTURING CAPACITY & UTILIZATION METRICS – helps you understand global biopharmaceutical production capacity trends, regional utilization rates, and the shift toward single-use bioreactors and optimized production efficiency.
- OUTSOURCING & STRATEGIC PARTNERSHIP TRENDS – helps you identify how pharmaceutical companies are increasing reliance on CMOs, including outsourcing penetration, contract value trends, and long-term manufacturing partnerships.
- BIOLOGICS DEVELOPMENT & REGULATORY BENCHMARKS – helps you analyze pipeline strength, clinical-stage distribution, approval timelines, and regulatory compliance performance across major markets.
- TECHNOLOGY ADOPTION & PROCESS INNOVATION – helps you uncover how continuous manufacturing, automation, and advanced analytics are transforming efficiency, scalability, and quality in biopharmaceutical production.
- BIOSIMILAR & NOVEL MODALITY PRODUCTION INSIGHTS – helps you evaluate biosimilar approval momentum, market entry timelines, and the expansion of CMOs into complex biologics and next-generation therapies.
- SUSTAINABILITY & NEXT-GEN MANUFACTURING INITIATIVES – helps you track green manufacturing adoption, energy-efficient production systems, and sustainable facility investments across the industry.
Purchase Single User PDF of Biopharmaceutical CMO Market Report (20% Discount): https://www.snsinsider.com/checkout/2938
Table of Contents – Major Key Points
1. Introduction
2. Executive Summary
3. Market Overview
4. Statistical Insights & Trends Reporting
5. Biopharmaceutical CMO Market Segmental Analysis & Forecast, By Source
6. Biopharmaceutical CMO Market Segmental Analysis & Forecast, By Service
7. Biopharmaceutical CMO Market Segmental Analysis & Forecast, By Product
8. Biopharmaceutical CMO Market Segmental Analysis & Forecast, By Region
9. Competitive Landscape
10. Analyst Recommendations
11. Assumptions
12. Disclaimer
13. Appendix
Access Complete Report Details of Biopharmaceutical CMO Market Analysis & Outlook: https://www.snsinsider.com/reports/biopharmaceutical-cmo-market-2938
[For more information or need any customization research mail us at info@snsinsider.com]
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
CONTACT: Contact Us: Rohan Jadhav - Principal Consultant Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: info@snsinsider.com
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. SingaporeOutlook.com takes no editorial responsibility for the same.
